Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Rapid Response Innovation Awards, 2014
    Electromyography Signals as Biomarkers for Parkinson’s Disease

    Objective/Rationale:
    A simple, painless and reliable method to detect Parkinson’s disease at an early stage is very important to patients, doctors and researchers. Doctors want to help patients early...

  • Research Grant, 2014
    Clinical and Neuroimaging Predictors of Cognitive Decline in Parkinson’s Disease

    Objective/Rationale:
    Parkinson’s disease (PD) dementia is often preceded by a phase of mild cognitive impairment (PD-MCI), for which diagnostic criteria have been recently proposed. However, there...

  • Access to Data and Biospecimens, 2014
    CRP40 Expression as a Biomarker of Parkinson’s Disease

    Objective/Rationale:            
    Alterations in HSPA9 gene expression has been described in Parkinson’s disease (PD). Ongoing studies suggest the expression of CRP40, a gene product of HSPA9, in the...

  • Research Grant, 2014
    CD163+ Macrophages as Tools for Neuroinflammatory Modulation in Parkinson’s Disease Supplement

    Promising Outcomes of Original Grant:
    Our fundamental hypothesis was that modulation of blood CD163+ macrophages using nanoparticles loaded with anti-inflammatory drugs could protect neurons in the...

  • Linked Efforts to Accelerate Parkinson’s Solutions, 2014
    Alpha-Synuclein Assay Standardization LEAPS

    Study Rationale:
    The presence of alpha-synuclein protein in biofluids such as blood, cerebrospinal fluid and saliva has been reported by multiple scientists using a variety of analytical techniques...

  • Target Validation, 2014
    Alpha-Galactosidase A as a Therapeutic Target for Parkinson’s Disease

    Objective/Rationale:             
    Alpha Galactosidase A (alpha-Gal A) is an enzyme that recycles lipids in cells. Our preliminary data demonstrates alpha-Gal A deficiency in brains of Parkinson’s...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.